Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera

Tofacitinib is the only medicine in the class of Janus kinase (JAK) inhibitors that has been approved for use in moderate-to-severely active ulcerative colitis (UC). The potential of other JAK inhibitors to treat UC has not been fully explored. We present a case describing the successful use of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Swei, Eric C., Fox, Charlie M., Bowles, Daniel W., Rizeq, Mona N., Onyiah, Joseph C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740881/
https://www.ncbi.nlm.nih.gov/pubmed/35018293
http://dx.doi.org/10.14309/crj.0000000000000741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740881/
https://www.ncbi.nlm.nih.gov/pubmed/35018293
http://dx.doi.org/10.14309/crj.0000000000000741

Ejemplares similares